ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Veterinary Pharmacology and Toxicology
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1676779
This article is part of the Research TopicTherapeutic Potential and Risks of Cannabinoids in Animal HealthView all 3 articles
Efficacy of a 20:1 CBD:THC Cannabis Herbal Extract for Pain and Inflammation in Dogs Following Tibial Plateau Levelling Osteotomy
Provisionally accepted- 1Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada
- 2Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada
- 3University of Saskatchewan College of Pharmacy and Nutrition, Saskatoon, Canada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study investigates the efficacy of 20:1 CBD:THC cannabis herbal extract (CHE) in reducing pain and improving mobility in dogs undergoing tibial plateau leveling osteotomy (TPLO) for cranial cruciate ligament rupture (CCLr). Methods: Forty-eight dogs were enrolled in a randomized, double-blinded, placebo-controlled clinical trial at the Western College of Veterinary Medicine between December 2022 and October 2024. Dogs were assigned to one of three treatment groups: placebo (flavored olive oil), 2 mg CBD (0.1 mg THC) /kg bw, or 5 mg CBD (0.25 mg THC)/kg bw. All dogs received a standard peri-and post-operative analgesic protocol consisting of opioids, nerve blocks, NSAIDs, and gabapentin. Veterinary assessments were performed on days +1 and +14 post-operatively and included Glasgow Composite Pain Scores (GCPS), stifle range of motion (ROM), thigh and stifle circumference, and gait symmetry ratios. Owners were advised to complete a modified Canine Brief Pain Inventory (CBPI) on days +3, +7, and +14. Plasma cannabinoid concentrations on Days 1 and 14 were analyzed using LC-MS/MS. Data were analyzed using linear mixed models and generalized estimating equations. Results: Forty-two dogs completed the study. All dogs had marked improvement in owner-reported pain scores from day +1 to day +14, regardless of treatment group. There were no significant differences in outcome measures between treatment groups. Potential treatment x day interactions were noted for ROM and gait symmetry; the high CHE dose group had marginally greater function on Day +1 but any effects did not persist to Day +14. No serious adverse events were reported; mild gastrointestinal effects (vomiting or diarrhea) were noted in seven cases. Owners reported the CHE doses were generally well tolerated. Plasma cannabinoid concentrations were highly variable and did not correlate with clinical outcomes. Clinical Significance: Overall, administration of an oral 20:1 CBD:THC cannabis herbal extract in addition to a standard analgesic protocol did not improve analgesia and limb function following TPLO surgery in dogs. Minor functional benefits may have occurred in the higher CHE dose group, but only on the first day following surgery. Current multimodal peri-and postoperative analgesic practices were effective, irrespective of CHE administration.
Keywords: Cannabinoids, CBD - cannabidiol, THC – tetrahydrocannabinol, TPLO – tibialplateau leveling osteotomy, cruciate repair, canine
Received: 31 Jul 2025; Accepted: 03 Sep 2025.
Copyright: © 2025 Lyons, Pinto, Penney, Holmes, Salama, Alcorn and Chicoine. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Alan Chicoine, Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.